The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...
NYSE stocks posting largest percentage decreases
AP - Tue Apr 15, 12:55PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.:
Notable Two Hundred Day Moving Average Cross - PBYI
MarketNewsVideo.com - Mon Apr 14, 3:22PM CDT
In trading on Monday, shares of Puma Biotechnology, Inc. crossed below their 200 day moving average of $74.19, changing hands as low as $71.12 per share.
3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Plenty of health-care stocks hit major headwinds this week. Few were blown away like these three, though. One of this week's major losers disappointed investors with mid-stage clinical results. Another had some big news that didn't seem to move...
Here's What's Behind Puma's Crash
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 11, 5:30PM CDT
Alan Auerbach, the former CEO of Cougar Biotechnology -- the company that developed Johnson & Johnson 's widely successful Zytiga prostate cancer drug -- hopes he has another blockbuster potential drug on his hands at Puma Biotechnology . ...
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:45AM CDT
Puma Biotechnology has seen negative consensus estimates for the current quarter along with a significant decline in its share price for the past month
NYSE stocks posting largest volume increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
Business Wire - Mon Apr 07, 12:31PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced the presentation of positive results from the Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. The presentation entitled "Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL" was presented today at the session entitled "Clinical Trials Symposium: Biomarker Driven Clinical Trials."